Literature DB >> 26043347

Designer benzodiazepines: A new challenge.

Bjoern Moosmann1,2, Leslie A King3, Volker Auwärter1.   

Abstract

Entities:  

Year:  2015        PMID： 26043347      PMCID： PMC4471986          DOI： 10.1002/wps.20236

Source DB:  PubMed          Journal:  World Psychiatry        ISSN： 1723-8617            Impact factor:   49.548


× No keyword cloud information.
  4 in total

1.  Novel psychoactive substances of interest for psychiatry.

Authors:  Fabrizio Schifano; Laura Orsolini; G Duccio Papanti; John M Corkery
Journal:  World Psychiatry       Date:  2015-02       Impact factor: 49.548

2.  Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics.

Authors:  Bjoern Moosmann; Philippe Bisel; Volker Auwärter
Journal:  Drug Test Anal       Date:  2014-03-06       Impact factor: 3.345

3.  Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics.

Authors:  Bjoern Moosmann; Laura M Huppertz; Melanie Hutter; Armin Buchwald; Sascha Ferlaino; Volker Auwärter
Journal:  J Mass Spectrom       Date:  2013-11       Impact factor: 1.982

4.  Use of alcohol and drugs to self-medicate anxiety disorders in a nationally representative sample.

Authors:  James Bolton; Brian Cox; Ian Clara; Jitender Sareen
Journal:  J Nerv Ment Dis       Date:  2006-11       Impact factor: 2.254
  4 in total
  10 in total

1.  New drug controls and reduced hospital presentations due to novel psychoactive substances in Edinburgh.

Authors:  Janice Pettie; Allan Burt; Duleeka W Knipe; Hazel Torrance; Margaret Dow; Karen Osinski; Robert Greig; Diletta Sabatini; Kate Easterford; James Dear; Michael Eddleston
Journal:  Br J Clin Pharmacol       Date:  2018-07-20       Impact factor: 4.335

2.  Characterization and identification of eight designer benzodiazepine metabolites by incubation with human liver microsomes and analysis by a triple quadrupole mass spectrometer.

Authors:  Souleiman El Balkhi; Maxime Chaslot; Nicolas Picard; Sylvain Dulaurent; Martine Delage; Olivier Mathieu; Franck Saint-Marcoux
Journal:  Int J Legal Med       Date:  2017-02-04       Impact factor: 2.686

3.  The designer benzodiazepine, flubromazepam, induces reward-enhancing and cardiotoxic effects in rodents.

Authors:  Eunchong Hong; Sun Mi Gu; Jin Mook Kim; Kyung Sik Yoon; Jin-Moo Lee; Young-Hoon Kim; Soo Kyung Suh; Dohyun Lee; Heejong Eom; Jaesuk Yun; Hye Jin Cha
Journal:  Toxicol Res (Camb)       Date:  2022-07-08       Impact factor: 2.680

4.  Harm Reduction From Below: On Sharing and Caring in Drug Use.

Authors:  Inge Van Schipstal; Swasti Mishra; Moritz Berning; Hayley Murray
Journal:  Contemp Drug Probl       Date:  2016-07-29

Review 5.  Metabolites replace the parent drug in the drug arena. The cases of fonazepam and nifoxipam.

Authors:  Maria Katselou; Ioannis Papoutsis; Panagiota Nikolaou; Chara Spiliopoulou; Sotiris Athanaselis
Journal:  Forensic Toxicol       Date:  2016-09-17       Impact factor: 4.096

6.  Synthesis of new tricyclic 5,6-dihydro-4H-benzo[b][1,2,4]triazolo[1,5-d][1,4]diazepine derivatives by [3+ + 2]-cycloaddition/rearrangement reactions.

Authors:  Lin-Bo Luan; Zi-Jie Song; Zhi-Ming Li; Quan-Rui Wang
Journal:  Beilstein J Org Chem       Date:  2018-07-18       Impact factor: 2.883

Review 7.  'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports.

Authors:  Laura Orsolini; John M Corkery; Stefania Chiappini; Amira Guirguis; Alessandro Vento; Domenico De Berardis; Duccio Papanti; Fabrizio Schifano
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

Review 8.  Novel Designer Benzodiazepines: Comprehensive Review of Evolving Clinical and Adverse Effects.

Authors:  Amber N Edinoff; Catherine A Nix; Amira S Odisho; Caroline P Babin; Alyssa G Derouen; Salim C Lutfallah; Elyse M Cornett; Kevin S Murnane; Adam M Kaye; Alan D Kaye
Journal:  Neurol Int       Date:  2022-08-22

9.  A Difficult Challenge for the Clinical Laboratory: Accessing and Interpreting Manufacturer Cross-Reactivity Data for Immunoassays Used in Urine Drug Testing.

Authors:  Justine M Reschly-Krasowski; Matthew D Krasowski
Journal:  Acad Pathol       Date:  2018-11-21

10.  The slippery slope of flubromazolam: Experiences of a novel psychoactive benzodiazepine as discussed on a Swedish online forum.

Authors:  Martin Andersson; Anette Kjellgren
Journal:  Nordisk Alkohol Nark       Date:  2017-05-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.